PUS7 and pancreatic adenocarcinoma: The results demonstrated that high PUS7 expression was positively associated with increased sensitivity to several drugs, including Raloxifene, Bafetinib, Dimethylaminoparthenolide and Nilotinib, suggesting these agents may have greater therapeutic efficacy in PAAD patients with elevated PUS7 expression.